论文部分内容阅读
目的探讨在糖尿病肾病治疗中缬沙坦、贝那普利联合应用的效果。方法 80例患者均为随机选取的2014年1月~2015年10月在本院接受治疗的糖尿病肾病患者,分为联合治疗组和对照组,每组40例,在有效控制血糖的基础上仅给予对照组缬沙坦治疗,在对照组的基础上再给予联合治疗组贝那普利治疗,对两组治疗后各项指标加以对比分析。结果相较于对照组,治疗后联合治疗组患者的Um ALb、UTRF、Cys-C水平更低,组间差异具有统计学意义(P<0.05)。但两组不良反应发生率不具有统计学差异(P>0.05)。结论相较于单一用药,缬沙坦、贝那普利联合应用可以使糖尿病肾病患者得到更好的治疗效果,且不会增加不良反应,具有在临床上广泛应用的价值。
Objective To investigate the combined effect of valsartan and benazepril in the treatment of diabetic nephropathy. Methods Eighty patients were randomized patients with diabetic nephropathy who were treated in our hospital from January 2014 to October 2015. They were divided into the combination therapy group and the control group, with 40 cases in each group. Based on the effective control of blood glucose Give the control group valsartan treatment, on the basis of the control group and then given the combination therapy group benazepril treatment, the two groups of indicators after treatment were compared. Results Compared with the control group, the levels of Um ALb, UTRF and Cys-C in the combined treatment group were lower after treatment, with statistical significance (P <0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Compared with a single drug, valsartan and benazepril combined can make patients with diabetic nephropathy better therapeutic effect, and does not increase adverse reactions, has clinical value widely.